Dr. Radhakrishnan Iyer, (Kris) is the Chief Scientific Officer of RIGImmune Inc. and has more than 30 years of experience in the Biopharmaceutical Industry in drug discovery and development. Kris is considered a leading innovator in the fields of nucleic acid chemistry and pharmaceutical sciences with over 100 publications and 250 issued as well as filed US and international patents. Prior to RIGImmune, Kris was the co-founder and CSO of Spring Bank Pharmaceuticals Inc., co-founder and CSO of Origenix Technologies Inc., and was the Associate Director of the Antisense Discovery group at Hybridon Inc. He has led multidisciplinary teams in the advancement of several small molecule and oligonucleotide drug candidates from discovery into clinical development in diverse therapeutic areas including antivirals, immuno-oncology, and inflammation. Kris is a fellow of the Royal Society of Chemistry, UK and the International Society of Physical Sciences, recipient of the M.L. Khorana Memorial Award, the ICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences, and is an adjunct professor at the Institute of Chemical Technology. Dr. Iyer has been a member of the Scientific Advisory Board of Biotechnology companies and has served on the NIH review panel for grants and contracts. Previously, Dr. Iyer was a Professor of Medicinal Chemistry at the University of Bombay, Visiting scientist at the CVER, FDA, and an Assistant Professor at the University of Texas, M.D. Anderson Cancer Center. Dr. Iyer carried out postdoctoral work at the Oak Ridge National Laboratory and at Johns Hopkins University.